Auro Laboratories Ltd. (BSE: 530233) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹132 Cr, it ranks #2,996 by market cap among the 6,189 Indian listed companies on FinBizNet, and #61 of 86 in Medicinal Chemicals and Botanical Products. At ₹212.35 (as of 26 Oct 2026), the share price is 33.0% below its 52-week high of ₹317.00 and 33.6% above its 52-week low of ₹159.00. The share price is down 3.2% over one year and down 12.9% over three months.
| Current Price | ₹212.35 |
|---|---|
| Market Cap | ₹132 Cr |
| BSE Code | 530233 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 37.5 |
| Return on Equity | 7.91% |
| Return on Assets | 4.20% |
| 52-Week Range | ₹159.00 – ₹317.00 |
| 1-Year Price Change | -3.2% |
| 3-Month Price Change | -12.9% |
| Beta (1Y) | 0.25 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aurolabs.com |
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers antihistamine; muscle relaxant; diuretic; iron deficiency; anti-diabetic, including Metformin HCL; anti-fungal, ulcer, malaria, and inflammatory; iodine supplement; analgesics; antacids; potassium and sodium iodide; and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. The co
1. Pharmaceuticals-This segment manufactures and sells generic active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Auro Laboratories Ltd. | ₹132 Cr | 37.5 | 7.91% | — | -3.2% |
Listed by market capitalisation. Ratios are shown for context only.
Auro Laboratories Ltd. is trading at ₹212.35, with a market capitalisation of ₹132 Cr.
Auro Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Auro Laboratories Ltd. has a P/E of 37.5 and a return on equity of 7.91%.
Auro Laboratories Ltd. is listed on the BSE under the scrip code 530233.
Auro Laboratories Ltd.'s share price is down 3.2% over one year and down 12.9% over three months. Its 52-week range is ₹159.00 to ₹317.00.
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.